Skip to content
CICTCL Insight
HomeAssessmentBiopsy resultsClinical tools

Search CTCL Insight

Saved encountersStandalone risk calculatorCTCL informationGuidelines and resourcesTreatment referenceAbout CTCL Insight

MF/SS Staging Tool

MF/SS only. Enter clinician-established categories, not findings inferred from missing tests. N1 to N3 require histopathologic assessment; enlarged nodes alone cannot assign them.

ISCL/USCLC/EORTC staging update (2022), Table 2

The 2022 update uses absolute aberrant-cell counts for blood class and records clonality separately. A matching skin and blood clone matters for Sézary diagnosis. The app omits subcategories and does not diagnose Sézary syndrome.

ISCL/USCLC/EORTC staging update (2022), Table 2

Stage undetermined

Complete, supported TNMB categories are required. Unknown or unassessed categories are not negative findings.

ISCL/USCLC/EORTC stage groups (2011), Table 2

App convention: any unknown category withholds the overall stage for specialist review, even when a known compartment may establish advanced disease. This is not a published staging rule.

TNMB reference

Skin

  • T1: Limited patches/plaques covering <10% of skin surface
  • T2: Patches/plaques covering ≥10% of skin surface
  • T3: One or more tumors ≥1 cm with deep infiltration or vertical growth
  • T4: Confluence of erythema covering ≥80% of body surface area

Nodes

  • Not assessed: App option: no nodal assessment recorded
  • Nx: Abnormal nodes without pathologic determination
  • N0: No clinically abnormal peripheral lymph nodes
  • N1: Clinically abnormal nodes; Dutch grade 1 (NCI LN0-2)
  • N2: Clinically abnormal nodes; Dutch grade 2 (NCI LN3)
  • N3: Clinically abnormal nodes; Dutch grade 3-4 (NCI LN4)

Viscera

  • Unassessed: Visceral involvement neither confirmed nor refuted; assessment incomplete
  • M0: No visceral organ involvement
  • M1: Clinician-established visceral involvement; document involved organs and confirmation method

Blood

  • Bx / unassessed: Blood burden cannot be quantified or has not been assessed
  • B0: <250/μL CD4+CD26− (or CD4+CD7−) cells; no significant blood involvement
  • B1: Low blood tumor burden; does not meet criteria for B0 or B2 (250 to <1000/μL)
  • B2: High blood tumor burden; ≥1000/μL CD4+CD26− (or CD4+CD7−) cells or another aberrant population by flow cytometry; assess clonality separately
ISCL/USCLC/EORTC staging update (2022), Table 2

CTCL Insight · Clinical decision support

AboutFeedbackPrivacyInstall
HomeAssessResultsTools